Abstract

RNA-protein interactions (RPIs) are promising targets for developing new molecules of therapeutic interest. Nevertheless, challenges arise from the lack of methods and feedback between computational and experimental techniques during the drug discovery process. Here, we tackle these challenges by developing a drug screening approach that integrates chemical, structural and cellular data from both advanced computational techniques and a method to score RPIs in cells for the development of small RPI inhibitors; and we demonstrate its robustness by targeting Y-box binding protein 1 (YB-1), a messenger RNA-binding protein involved in cancer progression and resistance to chemotherapy. This approach led to the identification of 22 hits validated by molecular dynamics (MD) simulations and nuclear magnetic resonance (NMR) spectroscopy of which 11 were found to significantly interfere with the binding of messenger RNA (mRNA) to YB-1 in cells. One of our leads is an FDA-approved poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor. This work shows the potential of our integrative approach and paves the way for the rational development of RPI inhibitors.

Data availability

All data are available within the Article, Supplementary Files and Appendices, or available from the corresponding authors on reasonable request. Source data for figures 2, 4d, 7b, Figure 3-Figure supplement 3, Figure 8a, Figure 8-Figure supplement 1b-c, Figure 8-Figure supplement 4b-c, Appendix 5 Table 1 and Appendix 5 Figure 1 are also provided with the paper.

Article and author information

Author details

  1. Krystel El Hage

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    For correspondence
    krystel.elhage@unibas.ch
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4837-3888
  2. Nicolas Babault

    SYNSIGHT, Evry, France
    Competing interests
    Nicolas Babault, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Nicolas Babault is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  3. Olek Maciejak

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9594-9435
  4. Bénédicte Desforges

    Department of Chemistry, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  5. Pierrick Craveur

    SYNSIGHT, Evry, France
    Competing interests
    Pierrick Craveur, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Pierrick Craveur is affiliated with SYNSIGHT. The author has no financial interests to declare.".
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9274-4944
  6. Emilie Steiner

    laboratoire structure activité des biomolécules normales et pathologiques, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  7. Juan Carlos Rengifo-Gonzalez

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  8. Hélène Henrie

    SYNSIGHT, Evry, France
    Competing interests
    Hélène Henrie, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Hélène Henrie is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  9. Marie-Jeanne Clement

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  10. Vandana Joshi

    laboratoire structure activité des biomolécules normales et pathologiques, Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
  11. Ahmed Bouhss

    Structure-Activité des Biomolécules Normales et Pathologiques (SABNP), Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6492-1429
  12. Liya Wang

    Structure-Activité des Biomolécules Normales et Pathologiques (SABNP), Université Paris-Saclay, INSERM U1204, Evry, France
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7119-8665
  13. Cyril Bauvais

    SYNSIGHT, Evry, France
    Competing interests
    Cyril Bauvais, Synsight has acquired a license for the MT bench" patent (WO2016012451A1) concerning the industrial applications. Cyril Bauvais is affiliated with SYNSIGHT. The author has no financial interests to declare.".
  14. David Pastré

    SABNP, Université Paris-Saclay, INSERM U1204, Evry, France
    For correspondence
    david.pastre@univ-evry.fr
    Competing interests
    No competing interests declared.

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions (895024)

  • Krystel El Hage

Genopole (SATURNE 2020)

  • David Pastré

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, El Hage et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,357
    views
  • 501
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Krystel El Hage
  2. Nicolas Babault
  3. Olek Maciejak
  4. Bénédicte Desforges
  5. Pierrick Craveur
  6. Emilie Steiner
  7. Juan Carlos Rengifo-Gonzalez
  8. Hélène Henrie
  9. Marie-Jeanne Clement
  10. Vandana Joshi
  11. Ahmed Bouhss
  12. Liya Wang
  13. Cyril Bauvais
  14. David Pastré
(2023)
Targeting RNA:protein interactions with an integrative approach leads to the identification of potent YBX1 inhibitors
eLife 12:e80387.
https://doi.org/10.7554/eLife.80387

Share this article

https://doi.org/10.7554/eLife.80387

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Joar Esteban Pinto Torres, Mathieu Claes ... Yann G-J Sterckx
    Research Article

    African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.